维尔达格利普汀
磷酸西他列汀
医学
肠促胰岛素
二肽基肽酶-4
二肽基肽酶
沙沙利汀
药理学
利格列汀
艾塞那肽
糖尿病
2型糖尿病
生物信息学
内分泌学
生物化学
酶
化学
生物
出处
期刊:Clinical Diabetes
[American Diabetes Association]
日期:2008-04-01
卷期号:26 (2): 53-57
被引量:51
标识
DOI:10.2337/diaclin.26.2.53
摘要
IN BRIEF Sitagliptin is the first agent in a new category of medications, the dipeptidyl peptidase-IV (DPP-IV) inhibitors. It was recently approved in the United States for the management of hyperglycemia in patients with type 2 diabetes; vildagliptin, a second agent in this class, is likely to join it on the U.S. market soon. These compounds accentuate the activity of endogenously produced antihyperglyemic incretin hormones and are generally well tolerated. This article provides an overview of the pharmacology and clinical use of the DPP-IV inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI